logo

EYPT

EyePoint·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

EYPT fundamentals

EyePoint (EYPT) released its earnings on Nov 5, 2025: revenue was 966.00K (YoY -90.82%), missed estimates; EPS was -0.85 (YoY -57.41%), missed estimates.
Revenue / YoY
966.00K
-90.82%
EPS / YoY
-0.85
-57.41%
Report date
Nov 5, 2025
EYPT Earnings Call Summary for Q3,2025
  • First-to-market momentum: DURAVYU Phase III trials fully enrolled; wet AMD data expected mid-2026, DME trials to begin Q1 2026.
  • Multi-MOA differentiation: VEGF, PDGF, and IL-6 inhibition; Phase II DME trial showed 6-month durability with 1 injection.
  • Strong financial position: $204M cash; $172M raised to fund DME trials through Q4 2027.
  • Clinical rigor: Blended endpoints reduce variability; non-inferiority vs. aflibercept with potential for superiority.
EPS
Revenue

Revenue & Expenses

EYPT has released its 2025 Q3 earnings report, with revenue of 966.00K, reflecting a YoY change of -90.82%, and net profit of -59.73M, showing a YoY change of -103.44%. The Sankey diagram below clearly presents EYPT's revenue sources and cost distribution.

Key Indicators

EyePoint (EYPT) key financial stats and ratios, covering profitability, financial health, and leverage.
EyePoint (EYPT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
EyePoint (EYPT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
EyePoint (EYPT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does EyePoint (EYPT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track EyePoint (EYPT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield